FDA clears oral semaglutide pill
The FDA approved oral semaglutide as the first GLP‑1 pill for weight loss, expanding options beyond injectables. (ajmc.com) Coverage also recommends strength training to help preserve muscle for people using GLP‑1s, with guidance on practical signs of maintained function. (indianexpress.com)
The Food and Drug Administration approved a daily pill version of semaglutide on Dec. 22, 2025, giving obesity treatment its first oral glucagon-like peptide-1 option in the United States. (fda.gov, prnewswire.com) Semaglutide is a drug that copies a gut hormone that lowers appetite, slows stomach emptying, and helps people eat less. The new tablet is sold as Wegovy and is approved with a reduced-calorie diet and increased physical activity for adults with obesity, or adults with overweight plus at least one weight-related condition. (fda.gov, health.usnews.com) The Food and Drug Administration label says Wegovy tablets are also approved to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. The tablet must be taken once each morning, and patients are told to wait at least 30 minutes before eating, drinking, or taking other oral medicines. (fda.gov, drugs.com) The approval widens a market that had been dominated by weekly injections such as Wegovy. Novo Nordisk said in December 2025 that it planned a U.S. launch in early January 2026. (prnewswire.com, usatoday.com) The evidence behind the pill came from late-stage obesity trials of oral semaglutide. In OASIS 1, adults without diabetes who took oral semaglutide 50 milligrams for 68 weeks lost 15.1% of body weight on average, versus 2.4% with placebo. (theLancet.com, acc.org) The Food and Drug Administration label for the approved tablet uses a different dosing plan, with a 25 milligram maintenance dose after step-up doses of 1.5, 4, and 9 milligrams. The label says the tablet safety study included 204 adults treated for up to 64 weeks. (fda.gov, wegovy.com) Like the injectable version, the tablet carries a boxed warning about thyroid C-cell tumors seen in rodents. It is contraindicated for patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. (fda.gov) Weight lost on glucagon-like peptide-1 drugs does not come only from fat. U.S. News reported in March 2026 that clinicians advise resistance training and higher protein intake because some lean muscle is commonly lost during rapid weight loss on drugs such as Wegovy and Zepbound. (health.usnews.com) Doctors quoted in that coverage pointed to simple function checks, including whether patients can keep doing squats, push-ups, planks, and everyday tasks such as climbing stairs or carrying groceries. The new pill removes the needle, but the basic advice stays the same: lose weight, keep strength. (health.usnews.com)
